Replimune Group, Inc.
NASDAQREPL heads into its June 4 earnings with one of the most combustible positioning setups in small-cap biotech: a heavily shorted stock that has tripled in a month. The short-side squeeze pressure is genuine. Short interest has climbed 43% over the past month to reach 33.4% of the free float — more than one in three shares sold short. Yet the stock closed at $9.00 on Monday, up 83%…
REPL cost to borrow surges to 0.50% — up 138% over one week amid heavy short interest of 24.6% of float.
Snapshot as of 21 Jun 2026
REPL heads into its June 4 earnings with one of the most combustible positioning setups in small-cap biotech: a heavily shorted stock that has tripled in a month. The short-side squeeze pressure is genuine. Short…
Replimune Group enters its May 15 earnings report in one of the most electrically charged setups in the biotech space right now: a 43% weekly surge, a third of the float still sold short, and call buyers running the…
Replimune Group heads into its May 15 earnings with nearly a quarter of its free float sold short — a position that has been building quietly since a devastating regulatory setback in April. Short interest commands the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for REPL — free to start on ORTEX.
Sign up for free →Open REPL on ORTEX